Advancing the Boundaries of Immunotherapy in Lung Adenocarcinoma with Idiopathic Pulmonary Fibrosis by a Biomimetic Proteinoid Enabling Selective Endocytosis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Advancing the Boundaries of Immunotherapy in Lung Adenocarcinoma with Idiopathic Pulmonary Fibrosis by a Biomimetic Proteinoid Enabling Selective Endocytosis

Published:2024-02-06 Issue: Volume: Page:
ISSN:1936-0851
Container-title:ACS Nano
language:en
Short-container-title:ACS Nano

Author:

Jiang Aimin¹,Zheng Xiaoqiang¹²,Yan Siqi²,Yan Jin³^ORCID,Yao Yu¹,He Wangxiao¹⁴^ORCID

Affiliation:

1. Department of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, China

2. Institute for Stem Cell & Regenerative Medicine, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004, China

3. National & Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004, China

4. Department of Talent Highland, The First Affiliated Hospital of Xi’an Jiao Tong University, Xi’an 710061, China

Funder

Xi?an Jiaotong University

National Key Research and Development Program of China

National Natural Science Foundation of China

Thousand Talents Plan of Shaanxi Province

Key Research and development program of Shaanxi Province

Innovation Capability Support Program of Shaanxi

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acsnano.3c09852

Reference46 articles.

1. Strategies to overcome resistance to immune checkpoint blockade in lung cancer

2. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

3. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

4. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

5. Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Editorial: Overcoming obstacles of cancer immunotherapy: the important role of emerging nanomedicine;Frontiers in Oncology;2024-04-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3